Fixed dose artesunate amodiaquine - A phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Ogutu, Bernhards ^a   Juma, Elizabeth ^a   Obonyo, Charles ^a   Jullien, Vincent ^b,c   Carn, Gwenaelle ^d   Vaillant, Michel ^e   Taylor, Walter Robert John ^f   Kiechel, Jean René ^d  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b INSERM   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d Drugs for Neglected Diseases Initiative   (Switzerland)

^e Public Research Centre for Health   (Luxembourg)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Amodiaquine; ECG; Kenya; Malaria; Pharmacokinetics

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTESUNATE; BILIRUBIN; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ; HEMOGLOBIN; QUININE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; ELECTROCARDIOGRAM; ELIMINATION RATE CONSTANT; FEMALE; FOLLOW UP; HEART RATE; HUMAN; IN VIVO STUDY; KENYAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PARASITE CLEARANCE; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POLYMERASE CHAIN REACTION; PRURITUS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT INFECTION; RHINITIS; TREATMENT OUTCOME; VERTIGO; VOLUME OF DISTRIBUTION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; KENYA; MALARIA, FALCIPARUM; MIDDLE AGED; PARASITOLOGY; PATHOLOGY; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; KENYA; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84924283120     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-498     Document Type: Article

References (60)

1. Kiechel JR, Pecoul B: ASAQ, a breakthrough in the fight against malaria. Med Trop (Mars) 2007, 67:109-110.
2. Bompart F, Kiechel JR, Sebbag R, Pecoul B: Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience. Malar J 2011, 10:143.
3. Taylor WR, Terlouw DJ, Olliaro PL, White NJ, Brasseur P, ter Kuile FO: Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. Bull World Health Organ 2006, 84:956-964.
4. Brasseur P, Agnamey P, Gaye O, Cisse M, Badiane M, Vaillant M, Taylor WR, Olliaro P: Dosing accuracy of artesunate and amodiaquine as treatment for falciparum malaria in Casamance, Senegal. Trop Med Int Health 2009, 14:79-87.
5. Faucher JF, Aubouy A, Adeothy A, Cottrell G, Doritchamou J, Gourmel B, Houze P, Kossou H, Amedome H, Massougbodji A, Cot M, Deloron P: Comparison of sulfadoxine-pyrimethamine, unsupervised artemetherlumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated Plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial. J Infect Dis 2009, 200:57-65.
6. Sirima SB, Tiono AB, Gansane A, Diarra A, Ouedraogo A, Konate AT, Kiechel JR, Morgan CC, Olliaro PL, Taylor WR: The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum. Malar J 2009, 8:48.
7. Faye B, Kuete T, Kiki-Barro CP, Tine RC, Nkoa T, Ndiaye JL, Kakpo CA, Sylla K, El Menan H, Gaye O, Faye O, Same-Ekobo A, Moussa K: Multicentre study evaluating the non-inferiority of the new paediatric formulation of artesunate/amodiaquine versus artemether/lumefantrine for the management of uncomplicated Plasmodium falciparum malaria in children in Cameroon, Ivory Coast and Senegal. Malar J 2012, 11:433.
8. Espie E, Lima A, Atua B, Dhorda M, Flevaud L, Sompwe EM, Palma Urrutia PP, Guerin PJ: Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial. Malar J 2012, 11:174.
9. Gbotosho GO, Sowunmi A, Okuboyejo TM, Happi CT, Folarin OA, Michael OS, Adewoye EO: Therapeutic efficacy and effects of artemether-lumefantrine and artesunate-amodiaquine coformulated or copackaged on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in Southwest Nigeria. Am J Trop Med Hyg 2011, 84:813-819.
10. Djalle D, Njuimo SP, Manirakiza A, Laganier R, Le Faou A, Rogier C: Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazinepyrimethamine and artesunate + amodiaquine and sulphadoxinepyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial. Malar J 2014, 13:9.
11. Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, Randrianasolo L, Ratsimbasoa A, Forlemu D, Moor VA, Traore A, Dicko Y, Dara N, Lameyre V, Diallo M, Djimde A, Same-Ekobo A, Gaye O: Randomized, multicentre assessment of the efficacy and safety of ASAQ-a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar J 2009, 8:125.
12. Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Greenhouse B, Staedke SG, Kamya MR, Dorsey G, Rosenthal PJ: Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children. PLoS One 2010, 5:e11759.
13. Bonnet M, Roper C, Felix M, Coulibaly L, Kankolongo GM, Guthmann JP: Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zerekore. Malar J 2007, 6:54.
14. van den Broek I, Kitz C, Al Attas S, Libama F, Balasegaram M, Guthmann JP: Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo. Malar J 2006, 5:113.
15. Guthmann JP, Cohuet S, Rigutto C, Fortes F, Saraiva N, Kiguli J, Kyomuhendo J, Francis M, Noel F, MulembaM, Balkan S: High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola. Am J Trop Med Hyg 2006, 75:143-145.
16. Ibrahium AM, Kheir MM, Osman ME, Khalil IF, Alifrangis M, Elmardi KA, Malik EM, Adam I: Efficacies of artesunate plus either sulfadoxine-pyrimethamine or amodiaquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. Ann Trop Med Parasitol 2007, 101:15-21.
17. Ajayi IO, Browne EN, Bateganya F, Yar D, Happi C, Falade CO, Gbotosho GO, Yusuf B, Boateng S, Mugittu K, Cousens S, Nanyunja M, Pagnoni F: Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: a report from three study sites in sub-Saharan Africa. Malar J 2008, 7:190.
18. Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, Olliaro P, Ali AS, Bjorkman A: Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 2005, 41:1079-1086.
19. Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B, Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WR: Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 2002, 359:1365-1372.
20. Holmgren G, Hamrin J, Svard J, Martensson A, Gil JP, Bjorkman A: Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect Genet Evol 2007, 7:562-569.
21. Kabanywanyi AM, Mwita A, Sumari D, Mandike R, Mugittu K, Abdulla S: Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicatedmalaria in children in southern Tanzania. Malar J 2007, 6:146.
22. Hamour S, Melaku Y, Keus K, Wambugu J, Atkin S, Montgomery J, Ford N, Hook C, Checchi F: Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxinepyrimethamine and artesunate plus amodiaquine combinations. Trans R Soc Trop Med Hyg 2005, 99:548-554.
23. Abacassamo F, Enosse S, Aponte JJ, Gomez-Olive FX, Quinto L, Mabunda S, Barreto A, Magnussen P, Ronn AM, Thompson R, Alonso PL: Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trop Med Int Health 2004, 9:200-208.
24. Ndounga M, Mayengue PI, Casimiro PN, Loumouamou D, Basco LK, Ntoumi F, Brasseur P: Artesunate-amodiaquine efficacy in Congolese children with acute uncomplicated falciparum malaria in Brazzaville. Malar J 2013, 12:53.
25. Swarthout TD, van den Broek IV, Kayembe G, Montgomery J, Pota H, Roper C: Artesunate + amodiaquine and artesunate + sulphadoxinepyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. Trop Med Int Health 2006, 11:1503-1511.
26. Rwagacondo CE, Karema C, Mugisha V, Erhart A, Dujardin JC, Van Overmeir C, Ringwald P, D'Alessandro U: Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. Trop Med Int Health 2004, 9:1091-1098.
27. Bonnet M, Broek I, van Herp M, Urrutia PP, van Overmeir C, Kyomuhendo J, Ndosimao CN, Ashley E, Guthmann JP: Varying efficacy of artesunate +amodiaquine and artesunate+sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in-vivo studies. Malar J 2009, 8:192.
28. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJ: Amodiaquine alone, amodiaquine +sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemetherlumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005, 365:1474-1480.
29. Grandesso F, Hagerman A, Kamara S, Lam E, Checchi F, Balkan S, Scollo G, Durand R, Guthmann JP: Low efficacy of the combination artesunate plus amodiaquine for uncomplicated falciparum malaria among children under 5 years in Kailahun, Sierra Leone. Trop Med Int Health 2006, 11:1017-1021.
30. Adjei GO, Kurtzhals JA, Rodrigues OP, Alifrangis M, Hoegberg LC, Kitcher ED, Badoe EV, Lamptey R, Goka BQ: Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J 2008, 7:127.
31. Falade CO, Ogundele AO, Yusuf BO, Ademowo OG, Ladipo SM: High efficacy of two artemisinin-based combinations (artemetherlumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria. Trop Med Int Health 2008, 13:635-643.
32. Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, Sundaygar T, Zolia YM, Jones JJ, Comte E, Bruneel A, Branger M, Jullien V, Carn G, Kiechel JR, Ashley EA, Guérin PJ: Tolerability and safety of artesunateamodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County Liberia. Malar J 2013, 12:250.
33. Neftel KA, Woodtly W, Schmid M, Frick PG, Fehr J: Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed) 1986, 292:721-723.
34. Orrell C, Taylor WR, Olliaro P: Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate. Trans R Soc Trop Med Hyg 2001, 95:517-518.
35. Markham LN, Giostra E, Hadengue A, Rossier M, Rebsamen M, Desmeules J: Emergency liver transplantation in amodiaquine-induced fulminant hepatitis. Am J Trop Med Hyg 2007, 77:14-15.
36. Ngouesse B, Basco LK, Ringwald P, Keundjian A, Blackett KN: Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients. Am J Trop Med Hyg 2001, 65:711-716.
37. Adjei GO, Oduro-Boatey C, Rodrigues OP, Hoegberg LC, Alifrangis M, Kurtzhals JA, Goka BQ: Electrocardiographic study in Ghanaian children with uncomplicated malaria, treated with artesunate-amodiaquine or artemether-lumefantrine. Malar J 2012, 11:420.
38. White NJ, Looareesuwan S, Edwards G, Phillips RE, Karbwang J, Nicholl DD, Bunch C, Warrell DA: Pharmacokinetics of intravenous amodiaquine. Br J Clin Pharmacol 1987, 23:127-135.
39. Stepniewska K, Taylor W, Sirima SB, Ouedraogo EB, Ouedraogo A, Gansane A, Simpson JA, Morgan CC, White NJ, Kiechel JR: Population pharmacokinetics of artesunate and amodiaquine in African children. Malar J 2009, 8:200.
40. Obonyo CO, Ochieng F, Taylor WR, Ochola SA, Mugitu K, Olliaro P, ter Kuile F, Oloo AJ: Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double-blind, placebo-controlled trial. Trans R Soc Trop Med Hyg 2003, 97:585-591.
41. Holmgren G, Bjorkman A, Gil JP: Amodiaquine resistance is not related to rare findings of pfmdr1 gene amplifications in Kenya. Trop Med Int Health 2006, 11:1808-1812.
42. Zucker JR, Ruebush TK 2nd, Obonyo C, Otieno J, Campbell CC: The mortality consequences of the continued use of chloroquine in Africa: experience in Siaya, western Kenya. Am J Trop Med Hyg 2003, 68:386-390.
43. Obonyo CO, Vulule J, Akhwale WS, Grobbee DE: In-hospital morbidity and mortality due to severe malarial anemia in western Kenya. Am J Trop Med Hyg 2007, 77:23-28.
44. Thwing JI, Odero CO, Odhiambo FO, Otieno KO, Kariuki S, Ord R, Roper C, McMorrow M, Vulule J, Slutsker L, Newman RD, Hamel MJ, Desai M: In-vivo efficacy of amodiaquine-artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya. Trop Med Int Health 2009, 14:294-300.
45. Snounou G, Beck HP: The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol Today 1998, 14:462-467.
46. WHO: Guidelines for the Treatment of Malaria. Geneva, Switzerland: World Health Organization; 2006.
47. Edwards IR, Aronson JK: Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000, 356:1255-1259.
48. Krudsood S, Looareesuwan S, Tangpukdee N, Wilairatana P, Phumratanaprapin W, Leowattana W, Chalermrut K, Ramanathan S, Navaratnam V, Olliaro P, Vaillant M, Kiechel JR, Taylor WR: New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine. Antimicrob Agents Chemother 2010, 54:3730-3737.
49. Krudsood S, Looareesuwan S, Wilairatama P, Leowattana W, Tangpukdee N, Chalermrut K, Ramanathan S, Navaratnam V, Olliaro P, Vaillant M, Kiechel JR, Taylor WR: Effect of artesunate and mefloquine in combination on the Fridericia corrected QT intervals in Plasmodium falciparum infected adults from Thailand. Trop Med Int Health 2011, 16:458-465.
50. Jullien V, Ogutu B, Juma E, Carn G, Obonyo C, Kiechel JR: Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy. Antimicrob Agents Chemother 2010, 54:2611-2617.
51. Price RN, Nosten F, White NJ: Prolongation of the QTc interval in African children treated for falciparum malaria. Am J Trop Med Hyg 1998, 59:503.
52. Zwang J, Ndiaye JL, Djimde A, Dorsey G, Martensson A, Karema C, Olliaro P: Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa. Malar J 2012, 11:25.
53. Gupta RK, Van Vugt M, Paiphun L, Slight T, Looareesuwan S, White NJ, Nosten F: Short report: no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate. Am J Trop Med Hyg 2005, 73:267-268.
54. Mytton OT, Ashley EA, Peto L, Price RN, La Y, Hae R, Singhasivanon P, White NJ, Nosten F: Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria. Am J Trop Med Hyg 2007, 77:447-450.
55. Karunajeewa H, Lim C, Hung TY, Ilett KF, Denis MB, Socheat D, Davis TM: Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br J Clin Pharmacol 2004, 57:93-99.
56. van Vugt M, Ezzet F, Nosten F, Gathmann I, Wilairatana P, Looareesuwan S, White NJ: No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg 1999, 61:964-967.
57. Hietala SF, Bhattarai A, Msellem M, Roshammar D, Ali AS, Stromberg J, Hombhanje FW, Kaneko A, Bjorkman A, Ashton M: Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J Pharmacokinet Pharmacodyn 2007, 34:669-686.
58. Orrell C, Little F, Smith P, Folb P, Taylor W, Olliaro P, Barnes KI: Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur J Clin Pharmacol 2008, 64:683-690.
59. Navaratnam V, Ramanathan S, Wahab MS, Siew Hua G, Mansor SM, Kiechel JR, Vaillant M, Taylor WR, Olliaro P: Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers. Eur J Clin Pharmacol 2009, 65:809-821.
60. Aubouy A, Mayombo J, Keundjian A, Bakary M, Le Bras J, Deloron P: Lack of prediction of amodiaquine efficacy in treating Plasmodium falciparum malaria by in vitro tests. Am J Trop Med Hyg 2004, 71:294-296.